WaveLight Plus InnovEyes光线追踪引导LASIK矫正近视及近视散光的1年前瞻性研究
这项前瞻性非随机干预研究纳入800眼(400例)近视或近视散光患者,其中300眼为术前柱镜≥1.50 D的预设亚组,所有眼接受WaveLight Plus InnovEyes光线追踪引导的飞秒LASIK并随访12个月。结果显示术后12个月100%眼UDVA≥20/20、68%≥20/16,96.5%眼SE在±0.50 D内、100%在±1.00 D内,仅0.38%眼在1至12个月间SE变化>0.50 D。结论认为该平台在1年时展现优异的有效性、安全性、屈光精确性和稳定性,散光矫正精确且轴向对齐良好,包括较高散光眼。
要点
- 术后12个月100%眼UDVA≥20/20,68%≥20/16,有效性指数1.17±0.12。
- 96.5%眼SE在±0.50 D内、100%在±1.00 D内,预测性R²=0.99。
- 仅0.38%眼在1至12个月间SE变化>0.50 D,稳定性良好。
核心结论
- WL Plus LASIK在1年时展现优异的有效性、安全性、屈光精确性和稳定性。
- 该平台散光矫正精确、残余误差小、轴向对齐高,包括较高散光眼,是矫正近视及近视散光的有效可预测选择。
研究设计与样本
- 前瞻性、非随机干预性研究,共纳入800眼(400例)近视或近视散光患者。
- 预设亚组为300眼术前柱镜≥1.50 D。
- 所有眼接受飞秒LASIK,采用WaveLight Plus InnovEyes光线追踪引导治疗规划,整合多模态生物测量、断层成像和波前数据生成个体化消融轮廓。
- 随访12个月,全队列及高柱镜亚组散光结果采用Alpins矢量法评估。
主要发现
- 12个月时100%眼UDVA≥20/20,68%≥20/16,平均术后UDVA为-0.07±0.05 logMAR,有效性指数1.17±0.12。
- 安全性指数1.17±0.12,无眼CDVA下降≥2行。
- 96.5%眼SE在±0.50 D内、100%在±1.00 D内,平均术后SE为-0.08±0.24 D,预测性R²=0.99。
- 仅0.38%眼在1至12个月间SE变化>0.50 D。
- 残余散光≤0.50 D者全队列95.2%、高柱镜亚组91.7%;矢量分析示轻度欠矫(平均CI全队列0.94、亚组0.93)、低残余误差(平均DV全队列0.15 D、亚组0.21 D),亚组85%眼轴向误差在±5°内。
关键数值与推荐
- 有效性:12个月UDVA≥20/20达100%,≥20/16达68%。
- 安全性:安全指数1.17±0.12,无眼CDVA下降≥2行。
- 屈光精确性:SE在±0.50 D内96.5%、±1.00 D内100%,R²=0.99。
- 稳定性:1至12个月SE变化>0.50 D者仅0.38%。
- 散光矢量:平均CI全队列0.94、亚组0.93;平均DV全队列0.15 D、亚组0.21 D;亚组85%眼轴向误差在±5°内。
临床怎么用
- 对近视及近视散光患者,光线追踪引导LASIK可提供高预测性的屈光矫正和良好稳定性。
- 对术前柱镜≥1.50 D的较高散光眼,该平台仍能实现精确散光矫正和轴向对齐,可考虑作为选项。
- 术后残余散光≤0.50 D比例高,矢量分析提示轻度欠矫,临床可据此预期并沟通。
局限性
- 研究为非随机设计。
- 随访时间为12个月。
- 高柱镜亚组为预设亚组,样本为300眼。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the efficacy, safety, refractive accuracy, and stability of WaveLight Plus InnovEyes ray-tracing-guided LASIK (WL Plus LASIK) in myopia and myopic astigmatism. DESIGN: Prospective, non-randomized interventional study. SUBJECTS, PARTICIPANTS AND/OR CONTROLS: A total of 800 eyes of 400 patients with myopia or myopic astigmatism and a predefined subgroup of 300 eyes with preoperative cylinder ≥1.50 D was included. METHODS, INTERVENTION OR TESTING: All eyes underwent femtosecond LASIK using WaveLight Plus InnovEyes ray-tracing-guided treatment planning. Multimodal biometric, tomographic, and wavefront data were integrated to generate individualized ablation profiles by reconciling the wavefront-derived refraction with the cycloplegia-verified manifest refraction. Patients were followed for 12 months. Astigmatic outcomes in the entire cohort and high-cylinder subgroup were assessed using the Alpins vector method. MAIN OUTCOME MEASURES: Uncorrected distance visual acuity (UDVA), spherical equivalent (SE) accuracy, refractive stability, safety index and vector parameters including target-induced astigmatism (TIA), surgically induced astigmatism (SIA), correction index (CI), difference vector (DV) and angle of error (AoE). RESULTS: At 12 months, 100% of eyes achieved UDVA ≥ 20/20 and 68% achieved ≥ 20/16. Mean postoperative UDVA was -0.07 ± 0.05 logMAR, with an efficacy index of 1.17 ± 0.12. The safety index was 1.17 ± 0.12, with no eyes losing ≥ 2 lines of CDVA. Refractive accuracy was high, with 96.5% of eyes within ±0.50 D and 100% within ±1.00 D of target SE. Mean postoperative SE was -0.08 ± 0.24 D, with excellent predictability (R² = 0.99). Refractive stability was maintained, with only 0.38% of eyes showing >0.50 D change between 1 and 12 months. Residual astigmatism was ≤ 0.50 D in 95.2% of eyes overall and 91.7% in the high-cylinder subgroup. Vector analysis demonstrated mild undercorrection (mean CI 0.94 overall, 0.93 in subgroup), low residual error (mean DV 0.15 D overall, 0.21 D in subgroup), and high axis accuracy, with 85% of subgroup eyes within ± 5°. CONCLUSIONS: WL Plus LASIK demonstrated excellent efficacy, safety, refractive accuracy and stability at 1 year. The platform provided precise astigmatic correction with minimal residual error and high axis alignment, including in eyes with higher astigmatism, indicating that ray-tracing-guided LASIK was an effective and predictable option for the correction of myopia and myopic astigmatism.
引用
- Shetty R, Shah A, Singh P, et al. Stability, Safety, and Efficacy of WaveLight Plus InnovEyes Ray-Tracing-Guided LASIK in Myopia and Myopic Astigmatism: A One-Year Prospective Study. Am J Ophthalmol. 2026. PMID: 42722116. doi:10.1016/j.ajo.2026.09.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。